Kiora Pharmaceuticals, Inc. is a clinical development-stage company based in Encinitas, CA, specializing in the development of novel therapeutics for orphan retinal diseases with high unmet need. Their mission is to improve ocular health and restore vision for patients suffering from severe vision loss, particularly those with inherited or age-related retinal degeneration.
With a focus on developing innovative therapies, Kiora is publicly traded on the NASDAQ under the ticker symbol KPRX. Their pipeline includes KIO-301, a groundbreaking small molecule that has the potential to restore vision in patients with inherited or age-related retinal degeneration, as well as KIO-104, a small molecule DHODH inhibitor designed to treat immunologic eye diseases.
Generated from the website